Stay in control of your spending. These prices have no additional charges to UK mainland customers, not even shipping! * Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Austria. Typical lead time: 10-14 working days. Contact us for more accurate information.
Further Information
Documents
Show All
Further Information
Bioactivity:
BGC0222 is a novel Irinotecan prodrug. As a PEG-cRGD conjugated derivative of Irinotecan, BGC0222 enables the slow and steady release of Irinotecan. It binds to the αVβ3 target with an IC50 of 4.25 uM and has an IC50 of 58.7 uM for αVβ5. BGC0222 can induce angiogenesis and demonstrates significant antitumor activity in various tumors.
